Comparison of Exenatide and Metformin Monotherapy in Overweight/Obese Patients with Newly Diagnosed Type 2 Diabetes
Table 1
Baseline characteristics of the exenatide and metformin groups.
Parameters
Exenatide ()
Metformin ()
Age, y
45.77 ± 10.60
48.05 ± 8.04
0.097
Gender, males/females, n
64/46
71/49
0.880
Overweight/obesity, n
57/53
63/57
0.918
Body weight, kg
78.76 ± 10.01
77.98 ± 11.88
0.907
BMI, kg/m2
27.83 ± 2.38
27.57 ± 3.56
0.815
TC, mmol/L
5.21 ± 1.25
5.29 ± 1.22
0.664
LDL-C, mmol/L
3.07 ± 0.89
3.05 ± 0.90
0.864
HDL-C, mmol/L
1.12 ± 0.43
1.24 ± 0.29
0.087
TG, mmol/L
2.07 (1.27–3.99)
1.93 (1.32–2.75)
0.235
FBG, mmol/L
9.34 ± 3.27
9.10 ± 1.34
0.594
FINS, μIU/mL
9.50 (5.98–14.37)
10.14 (5.25–14.94)
0.337
HbA1c, %
9.11 ± 1.46
9.03 ± 1.18
0.230
HOMA-IR
3.94 (2.47–5.93)
3.87 (2.27–6.02)
0.638
HOMA-β
55.13 (29.64–76.65)
50.55 (29.80–74.81)
0.289
Data are means ± SD unless indicated otherwise. TG, FINS, HOMA-IR, and HOMA-β are shown as medians (upper and lower quartiles). BMI: body mass index; TC: total cholesterol; LDL-C: low-density lipoprotein cholesterol; HDL-C: high-density lipoprotein cholesterol; TG: triglyceride; FBG: fasting blood glucose; FINS: fasting insulin; HOMA-IR: homeostasis model assessment of insulin resistance; HOMA-β: homeostasis model assessment of β-cell function.
